These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31673326)

  • 1. Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives.
    Sardella M; Lungu C
    Ther Adv Drug Saf; 2019; 10():2042098619882819. PubMed ID: 31673326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
    Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
    Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.
    de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC
    Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of statistical signal detection procedures in eudravigilance post-authorization data: a retrospective evaluation of the potential for earlier signalling.
    Alvarez Y; Hidalgo A; Maignen F; Slattery J
    Drug Saf; 2010 Jun; 33(6):475-87. PubMed ID: 20486730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area.
    Grundmark B; Holmberg L; Garmo H; Zethelius B
    Eur J Clin Pharmacol; 2014 May; 70(5):627-35. PubMed ID: 24599513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Impact of Mandatory Reporting of Non-Serious Safety Reports to EudraVigilance on the Detection of Adverse Reactions.
    Candore G; Monzon S; Slattery J; Piccolo L; Postigo R; Xurz X; Strauss S; Arlett P
    Drug Saf; 2022 Jan; 45(1):83-95. PubMed ID: 34881404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EudraVigilance Medicines Safety Database: Publicly Accessible Data for Research and Public Health Protection.
    Postigo R; Brosch S; Slattery J; van Haren A; Dogné JM; Kurz X; Candore G; Domergue F; Arlett P
    Drug Saf; 2018 Jul; 41(7):665-675. PubMed ID: 29520645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
    Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
    Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative performance of two quantitative safety signalling methods: implications for use in a pharmacovigilance department.
    Almenoff JS; LaCroix KK; Yuen NA; Fram D; DuMouchel W
    Drug Saf; 2006; 29(10):875-87. PubMed ID: 16970511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
    Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
    Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of spontaneous reports on narcolepsy following administration of pandemic influenza vaccine; a case series of individual case safety reports in Eudravigilance.
    Gadroen K; Straus SMJM; Pacurariu A; Weibel D; Kurz X; Sturkenboom MCJM
    Vaccine; 2016 Sep; 34(41):4892-4897. PubMed ID: 27577558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of pharmacovigilance databases for spontaneous reports of adverse drug reactions related to substandard and falsified medical products: A descriptive study.
    Pozsgai K; Szűcs G; Kőnig-Péter A; Balázs O; Vajda P; Botz L; Vida RG
    Front Pharmacol; 2022; 13():964399. PubMed ID: 36147337
    [No Abstract]   [Full Text] [Related]  

  • 14. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study.
    Hoeve CE; van Haren A; Sturkenboom MCJM; Straus SMJM
    Vaccine; 2018 Dec; 36(52):7956-7964. PubMed ID: 30416019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tramadol-induced hiccups: a case-noncase study in the European pharmacovigilance database.
    García M; Lertxundi U; Aguirre C
    Ther Adv Drug Saf; 2021; 12():20420986211021230. PubMed ID: 34211690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection.
    Pacurariu AC; Straus SM; Trifirò G; Schuemie MJ; Gini R; Herings R; Mazzaglia G; Picelli G; Scotti L; Pedersen L; Arlett P; van der Lei J; Sturkenboom MC; Coloma PM
    Drug Saf; 2015 Dec; 38(12):1201-10. PubMed ID: 26370104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance.
    Monaco L; Melis M; Biagi C; Donati M; Sapigni E; Vaccheri A; Motola D
    Expert Opin Drug Saf; 2017 Mar; 16(3):271-275. PubMed ID: 28094583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety related drug-labelling changes: findings from two data mining algorithms.
    Hauben M; Reich L
    Drug Saf; 2004; 27(10):735-44. PubMed ID: 15350157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
    Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
    Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.